engleski

Rosuvastatin-induced rhabdomyolysis – the possible role of ticagrelor and the patient’s pharmacogenetic profile: a case report

Dual antiplatelet therapy and statins are the cornerstone of acute coronary syndrome (ACS) treatment. Interaction between these drugs can be affected by differences in inter- individual pharmacokinetics/pharmacogenetics. Rhabdomyolysis is adverse reaction of statins. Previous reports suggested that concomitant use of ticagrelor may add an additional risk in developing statin induced rhabdomyolysis. We present a case of rosuvastatin and ticagrelor induced rhabdomyolysis

rhabdomyolysis ; rosuvastatin ; ticagrelor

nije evidentirano